JP2001511763A - 尿失禁の治療のための5−ht▲下1a▼受容体アンタゴニストの使用 - Google Patents
尿失禁の治療のための5−ht▲下1a▼受容体アンタゴニストの使用Info
- Publication number
- JP2001511763A JP2001511763A JP53057997A JP53057997A JP2001511763A JP 2001511763 A JP2001511763 A JP 2001511763A JP 53057997 A JP53057997 A JP 53057997A JP 53057997 A JP53057997 A JP 53057997A JP 2001511763 A JP2001511763 A JP 2001511763A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- aryl
- hydrogen atom
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003727 serotonin 1A antagonist Substances 0.000 title abstract description 5
- 238000011282 treatment Methods 0.000 title description 13
- 206010046543 Urinary incontinence Diseases 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 121
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 74
- -1 and stereoisomers Chemical class 0.000 claims abstract description 62
- 230000001242 postsynaptic effect Effects 0.000 claims abstract description 21
- 230000003518 presynaptic effect Effects 0.000 claims abstract description 21
- 208000026723 Urinary tract disease Diseases 0.000 claims abstract description 7
- 208000014001 urinary system disease Diseases 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 146
- 125000003118 aryl group Chemical group 0.000 claims description 93
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 78
- 125000001072 heteroaryl group Chemical group 0.000 claims description 58
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 45
- 125000002619 bicyclic group Chemical group 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- 125000006413 ring segment Chemical group 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 54
- 150000004677 hydrates Chemical class 0.000 abstract description 2
- 210000003932 urinary bladder Anatomy 0.000 description 39
- 102000005962 receptors Human genes 0.000 description 38
- 108020003175 receptors Proteins 0.000 description 38
- 241000700159 Rattus Species 0.000 description 27
- 229940126062 Compound A Drugs 0.000 description 26
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 26
- 230000008602 contraction Effects 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 230000027939 micturition Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- SJDOMIRMMUGQQK-UHFFFAOYSA-N NAN 190 Chemical compound COC1=CC=CC=C1N1CCN(CCCCN2C(C3=CC=CC=C3C2=O)=O)CC1 SJDOMIRMMUGQQK-UHFFFAOYSA-N 0.000 description 14
- 238000001990 intravenous administration Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000002464 receptor antagonist Substances 0.000 description 11
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000009530 blood pressure measurement Methods 0.000 description 10
- 230000011514 reflex Effects 0.000 description 10
- 230000002485 urinary effect Effects 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000036724 intravesical pressure Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 230000001020 rhythmical effect Effects 0.000 description 9
- 108060003345 Adrenergic Receptor Proteins 0.000 description 8
- 102000017910 Adrenergic receptor Human genes 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 210000001635 urinary tract Anatomy 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 7
- 229960000855 flavoxate Drugs 0.000 description 7
- 229940044551 receptor antagonist Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000002631 hypothermal effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229960005434 oxybutynin Drugs 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 231100000086 high toxicity Toxicity 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000008967 Enuresis Diseases 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 206010013990 dysuria Diseases 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 210000003194 forelimb Anatomy 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 150000004885 piperazines Chemical class 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 125000001637 1-naphthyl group Chemical class [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000004659 Presynaptic Receptors Human genes 0.000 description 3
- 108010003717 Presynaptic Receptors Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036453 micturition reflex Effects 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000018360 neuromuscular disease Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000005070 sphincter Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- YZKSXUIOKWQABW-UHFFFAOYSA-N 4-piperazin-1-yl-1h-indole Chemical compound C1CNCCN1C1=CC=CC2=C1C=CN2 YZKSXUIOKWQABW-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- JDJSIZDLNNLMKE-UHFFFAOYSA-N n-(2-oxoethyl)-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound C=1C=CC=NC=1N(CC=O)C(=O)C1CCCCC1 JDJSIZDLNNLMKE-UHFFFAOYSA-N 0.000 description 2
- CXABFNVWAQDCAU-UHFFFAOYSA-N n-[2-[4-(1h-indol-4-yl)piperazin-1-yl]ethyl]pyridin-2-amine Chemical compound C1CN(C=2C=3C=CNC=3C=CC=2)CCN1CCNC1=CC=CC=N1 CXABFNVWAQDCAU-UHFFFAOYSA-N 0.000 description 2
- ZOOGISIXBJEBLV-UHFFFAOYSA-N n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]pyridin-2-amine Chemical compound COC1=CC=CC=C1N1CCN(CCNC=2N=CC=CC=2)CC1 ZOOGISIXBJEBLV-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229960001779 pargyline Drugs 0.000 description 2
- 210000003903 pelvic floor Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 125000006169 tetracyclic group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- AOSCUPVQGZCMHA-GFCCVEGCSA-N (3r)-3-[cyclobutyl(propan-2-yl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound CC(C)N([C@@H]1CC2=C(C(N)=O)C=CC(F)=C2OC1)C1CCC1 AOSCUPVQGZCMHA-GFCCVEGCSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- YKSVXVKIYYQWBB-UHFFFAOYSA-N 1-butylpiperazine Chemical compound CCCCN1CCNCC1 YKSVXVKIYYQWBB-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- MQBVUWSPBBINHW-UHFFFAOYSA-N 2-[4-(1h-indol-4-yl)piperazin-1-yl]-n-pyridin-2-ylacetamide Chemical compound C1CN(C=2C=3C=CNC=3C=CC=2)CCN1CC(=O)NC1=CC=CC=N1 MQBVUWSPBBINHW-UHFFFAOYSA-N 0.000 description 1
- NDVVQPVEUGLAPX-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)piperazin-1-yl]ethanamine Chemical compound COC1=CC=CC=C1N1CCN(CCN)CC1 NDVVQPVEUGLAPX-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 206010056948 Automatic bladder Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010005033 Bladder dilatation Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010005063 Bladder pain Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000662429 Fenerbahce Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 125000006286 dichlorobenzyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical group OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- NIBOMXUDFLRHRV-UHFFFAOYSA-N hydron;8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione;dichloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCN2C(CC3(CCCC3)CC2=O)=O)CC1 NIBOMXUDFLRHRV-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- HGJJGXSQJAMMIH-UHFFFAOYSA-N n-(2,2-dimethoxyethyl)-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound C=1C=CC=NC=1N(CC(OC)OC)C(=O)C1CCCCC1 HGJJGXSQJAMMIH-UHFFFAOYSA-N 0.000 description 1
- HIGNCIRDLMYFFM-UHFFFAOYSA-N n-(2,2-dimethoxyethyl)pyridin-2-amine Chemical compound COC(OC)CNC1=CC=CC=N1 HIGNCIRDLMYFFM-UHFFFAOYSA-N 0.000 description 1
- KSEUJIOIBWGIRY-UHFFFAOYSA-N n-[2-[2,3-dihydro-1,4-benzodioxin-3-ylmethyl(methyl)amino]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound C1OC2=CC=CC=C2OC1CN(C)CCN(C=1N=CC=CC=1)C(=O)C1CCCCC1 KSEUJIOIBWGIRY-UHFFFAOYSA-N 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MQTUXRKNJYPMCG-CYBMUJFWSA-N robalzotan Chemical compound C1CCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 MQTUXRKNJYPMCG-CYBMUJFWSA-N 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Spinning Or Twisting Of Yarns (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)少なくとも10-7Mの親和力を持っている5-HT1A受容体に結合し、 (b)α1-アドレナリン受容体に結合する親和力よりも少なくとも50倍強い親和 力を持って5-HT1A受容体に結合し、及び (c)シナプス前部5-HT1A受容体及びシナプス後部5-HT1A受容体の両方に対して 、5-HT1A受容体アンタゴニスト活性を示す 化合物、又はその化合物の立体異性体,水和物,溶媒和物もしくは薬学的に許容さ れる塩の哺乳動物における下部尿路の障害を治療する薬物を調製するための使用 。 2.一般式I [式中、 Raは水素原子又は低級アルキル基を示し; Ra1はアリール、含窒素ヘテロアリール又は二環式ヘテロアリール基を示し; Xaは下記の群のいずれか一つを示す。(式中、naは1又は2であり; maは1、2又は3であり; Ra2は水素原子又は低級アルキル基を示し; Ra3はアリール又はアリール(低級)アルキル基を示し; Ra4は水素原子又はC1-C3アルキル基を示し; Ra5は水素原子、C1-C3アルキル基、C3-C12シクロアルキル基又はシクロアルキル (低級)アルキル基を示すか;又はRa4及びRa5は、それらが結合している窒素原子 と共に、各々低級アルキル基,アリール基又はアリール(低級) アルキル基で置換されていてもよい、1-アゼチジニル基,1-ピロリジニル基,ピペ リジノ基,1-ペルヒドロアゼピニル基,モルホリノ基又は1-ピペラジニル基を示し ; Ra6は単環式又は二環式ヘテロアリール基を示し; Ra7は水素原子、低級アルキル基、シクロアルキル基、シクロアルケニル基、シ クロアルキル(低級)アルキル基、アリール基、アリール(低級)アルキル基、ヘテ ロアリール基もしくはヘテロアリール(低級)アルキル基又は原子団-NRa8Ra9もし くは原子団ORa10を示す; Ra8は水素原子又は低級アルキル基、アリール基又はアリール(低級)アルキル基 を示し; Ra9は水素原子又は低級アルキル基、-CO-(低級)アルキル基、アリール基、-CO- アリール基、アリール(低級)アルキル基、シクロアルキル基もしくはシクロアル キル(低級)アルキル基を示すか;又は、Ra8及びRa9が結合している窒素原子と共 に、付加したヘテロ原子を含んでいてもよい飽和複素環基を示し; Ra10は低級アルキル基、シクロアルキル基、シクロアルキル(低級)アルキル基、 アリール基、アリール(低級)アルキル基、ヘテロアリール基又はヘテロアリール (低級)アルキル基を示す; Ra11はアリール基又は含窒素ヘテロアリール基を示し; Ra12は水素原子又は低級アルキル基を示し; Ra13は水素原子又はC1-C3アルキル基、C3-C12シクロアルキル基もしくはシクロ アルキル(低級)アルキル基を示し; Ra14はアリール基を示し; Kaは一又はそれ以上の低級アルキル基で置換されていてもよいC2-C4アルキレン 基を示し; Yaはカルボニル基、アルキレン基、ヒドロキシアルキレン基又はヒドロキシシク ロアルキレン基、又は-S(O)oa基(oa0〜2)を示す。)] を有する化合物の請求項1に記載の使用。 3.1-[N-シクロヘキシルカルボニル-N-(2-ピリジル)-2-アミノエチル)-4-(2-メ トキシフェニル)-ピペラジンの請求項1に記載の使用。 4.1-[N-シクロヘキシルカルボニル-N-(2-ピリジル)-2-アミノエチル)-4-(4-イ ンドリル)-ピペラジンの請求項1に記載の使用。 5.一般式II[式中、 Qbは一もしくはそれ以上の低級アルキル基で置換されていてもよいC1-C3アルキ レン基を示し; Rb1は水素原子又は低級アルキル基を示し; Rb2は、 からなる原子団のいずれか一つを示すか; 又は、Rb1とRb2はそれらが結合している窒素原子と共に、を示し; Rb3は水素原子又は低級アルキル基を示し; Rb4はアリール基、二環式アリール基又はヘテロアリール基を示し; Rb5は水素原子又は低級アルキル基を示し; Rb6は水素原子又はC1-C10アルキル基、C3-C12シクロアルキル基、シクロアルキ ル(低級)アルキル基、アリール基もしくはアリール(低級)アルキル基を示すか; 又は、Rb5及びRb6はそれらが結合している窒素原子と共に、追加のヘテロ原子を 含んでいても、又ハロゲン原子又は低級アルキル基,アリール基,アリール(低級 )アルキル基,低級アルコキシ基,もしくはハロ(低級)アルキル基で置換されてい てもよい飽和複素環基を示す; abは0〜3であり、又bbは0〜3であるが、(ab+bb)は3より大きくない; の二重結合を示す; Xbは原子団-(CH2)nb-、-OCH2-又は-SCH2-を示し; mbは0又は1であり、nbは1〜3であり、pbは0又は1である; ただし、(mb+pb)が1であって、かつ(mb+nb)が3より大きくないことが条件である ; Rb7は水素もしくはハロゲン原子、又は低級アルキル基、(低級)アルキルカルボ ニル基、低級アルコキシ基、(低級)アルコキシカルボニル基、ヒドロキシ基、 トリフルオロメチル基、カルボキサミド基、ニトロ基、シアノ基、アミノ基、( 低級)アルキルアミノ基又はジ(低級)アルキルアミノ基を示し; Rb7'は水素もしくはハロゲン原子を示す;ただし、Xbが、原子団-OCH2-又は-SCH2 -である時は、Rb7'は水素原子である; Rb8は水素原子又は低級アルキル基を示し; ib=0、1又は2であり、jb=0、1又は2である; Ybは酸素もしくは硫黄原子又はメチレン基を示し; ZbはYb基を含む非芳香環と縮合した5〜7個の炭素原子を有するヘテロ芳香環を形 成するのに必要な原子を示し; Rb9は単環式又は二環式ヘテロアリール基を示し; Zb'は一対の水素原子、又はベンゾジオキサニル基と縮合した芳香環もしくはヘ テロ芳香環を形成するのに必要 な原子を示し;及び Rb10は単環式もしくは二環式アリール基、又は二環式ヘテロアリール基を示す。 ] を有する化合物の請求項1に記載の使用。 6.一般式III [式中、 Rc1はヘテロアリール基又は二環式ヘテロアリール基を示し; Rc2はシクロアルキル基を示し; Rc3は水素原子又は低級アルキル基を示し; Rc3'は水素原子又は低級アルキル基を示し; Rc4は水素原子又は低級アルキル基を示し;及び Rc5は請求項5で定義した原子団(Ab)、(Bb)、(Cb)、(Db)、(Eb)及び(Fb)のいず れか一つを示すか; 又は、Rc4及びRc5はそれらが結合している窒素原子と共に、式 た通りである。)の原子団を示す。] を有する化合物の請求項1に記載の使用。 7.一般式IV [式中、 Aeは原子団-OCH=CH-、-OCH2CH2-、-OCH2O-、-OCH2CH2O-又は-OCOCH=CH-を示し; 各Reは、独立して、水素もしくはハロゲン原子又はアルキル基、ヒドロキシ基、 アルコキシ基、トリフルオロメチル基又はシアノ基を示し; Keはアリール基もしくはヘテロアリール基で置換されていてもよいC1-C8の直鎖 状もしくは分枝状のアルキレン基を示し; Re1はフェニル基、チエニル基、ナフチル基もしくはベンゾチオフェニル基、又 は式 (式中、peは3又は4であり;qeは0〜3であり;reは0〜2であり;seは1又は2であ る; 各Re2は、独立してハロゲン原子又はアルキル基、ヒドロキシ基、アルコキシ基 、トリフルオロメチル基もしくはシアノ基を示し; Deは原子団-CH=CH-又は(CH2)2-4を示し;及び、 Xe1、Xe2及びXe3はそれぞれ独立して水素原子又はアルキル基、アルコキシ基、 ヒドロキシ基、アルキルチオ基、トリフルオロメチル基、ニトロ基、アミノ基も しくはアセトアミド基を示すか;又はXe1、Xe2及びXe3のうちの二つが、ともに 原子団-OCH2O−もしくは-OCH2CH2O-を示す。)の原子団を示す。] を有する化合物の請求項1に記載の使用。 8.一般式V [式中、 Rg1及びRg2は、それぞれ独立して水素もしくはハロゲン原子、又はトリフルオロ メチル基、もしくはC1-C4アルコキシ基を示すか; 又はRg1及びRg2は隣接する炭素原子上にあって、一緒に式-O(CH2)igO-(ig=1〜3) の原子団を示す; Rg3、Rg4及びRg5は、それぞれ独立して水素原子又はC1-C4アルキル基又はフェニ ル基を示し; Ygは窒素原子又は原子団CHを示し;及び Rg6はヘテロアリール基、フェニル基又は置換フェニル基を示す。] を有する化合物の請求項1に記載の記載の使用。 9.一般式VI [式中、 Ri1は水素原子、C1-C4アルキル基、C3-C4アルケニル基、フェニル(C1-C4)アルキ ル基、もしくはシクロプロピルメチル基、又は原子団CORi4、-(CH2)niS(C1-C4) アルキルもしくは-(CH2)niC(O)NRi9Ri10を示し; Ri2は水素原子又はC1-C4アルキル基、C3-C4アルケニル基もしくはシクロプロピ ルメチル基を示し; Aiはテトラゾリル基もしくは置換テトラゾリル基、1〜3個の酸素,硫黄もしくは 窒素原子を含んでいてもよい五又は六員環原子を有するヘテロアリール基、又は 原子団 を示し; Biは水素原子、C1-C4アルキル基又はアミノ−ブロッキング基を示し; Xiは水素原子、又は原子団-ORi3、-SRi3もしくは-NRi5Ri6を示し; Ri3はC1-C3アルキル基、置換C1-C3アルキル基、アリール基、置換アリール基、 アリール(C1-C4)アルキル基、置換アリール(C1-C4)アルキル基又はC3-C7シクロ アルキル基を示し; Ri4は水素原子又はC1-C4アルキル基、C1-C4ハロアルキル基、C1-C4アルコキシ基 もしくはフェニル基を示し; Ri5及びRi6は、それぞれ独立して水素原子又はC1-C4アルキル基、フェニル(C1-C4 )アルキル基もしくはフェニル基を示すか; 又は、Ri5及びRi6は、それらが結合している窒素原子と共に、C3-C5複素環を示 す; Ri9及びRi10は、それぞれ独立して、水素原子又はC1-C4アルキル基もしくはC5-C8 シクロアルキル基を示し; niは1〜4であり;及び、 Qiは酸素もしくは硫黄原子を示す。] を有する化合物の請求項1に記載の使用。 10.一般式VII [式中、 Rd1はn-プロピル基又はシクロブチル基を示し; Rd2はイソプロピル基、t-ブチル基、シクロブチル基、シクロペンチル基又はシ クロヘキシル基を示し;及び Rd3は水素原子又はメチル基を示す。] を有する化合物の請求項1に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT96A000378 | 1996-02-28 | ||
IT96MI000378A IT1282705B1 (it) | 1996-02-28 | 1996-02-28 | Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria |
PCT/EP1997/000897 WO1997031637A1 (en) | 1996-02-28 | 1997-02-25 | Use of 5-ht1a receptor antagonists for the treatment of urinary incontinence |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001511763A true JP2001511763A (ja) | 2001-08-14 |
Family
ID=11373430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53057997A Ceased JP2001511763A (ja) | 1996-02-28 | 1997-02-25 | 尿失禁の治療のための5−ht▲下1a▼受容体アンタゴニストの使用 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0906100B1 (ja) |
JP (1) | JP2001511763A (ja) |
AT (1) | ATE258438T1 (ja) |
AU (1) | AU2093297A (ja) |
DE (1) | DE69727378T2 (ja) |
DK (1) | DK0906100T3 (ja) |
ES (1) | ES2213205T3 (ja) |
IT (1) | IT1282705B1 (ja) |
PT (1) | PT906100E (ja) |
WO (1) | WO1997031637A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156780A (en) * | 1996-10-17 | 2000-12-05 | Milkhaus Laboratory, Inc. | Treatment of fecal incontinence |
SE510305C2 (sv) | 1997-05-30 | 1999-05-10 | Astra Ab | Nytt salt |
WO1999003833A1 (en) * | 1997-07-15 | 1999-01-28 | Sankyo Company, Limited | Piperazine derivatives |
US6906069B1 (en) | 1999-01-08 | 2005-06-14 | Amgen Inc. | LXR modulators |
AU2000235960A1 (en) * | 2000-02-14 | 2001-08-27 | Tularik, Inc. | Lxr modulators |
US6673543B2 (en) | 2000-04-05 | 2004-01-06 | Tularik, Inc. | Solid phase synthesis of LXR ligands |
ES2275853T3 (es) * | 2001-02-16 | 2007-06-16 | Aventis Pharmaceuticals Inc. | Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3. |
MXPA04002496A (es) * | 2001-09-27 | 2004-05-31 | Pharmacia Ab | Composicion farmaceutica para el tratamiento de enfermedades urinarias. |
CA2474702A1 (en) | 2002-01-30 | 2003-08-07 | Tularik Inc | Heterocyclic arylsulfonamidobenzylic compounds |
CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
JPWO2006082872A1 (ja) * | 2005-02-04 | 2008-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 1−(ピペリジン−4−イル)−1h−インドール誘導体 |
JP4932717B2 (ja) | 2005-05-11 | 2012-05-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピペリジン環を有するインドール誘導体の製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
EP0558245A1 (en) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors |
GB9411099D0 (en) * | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9417135D0 (en) * | 1994-08-23 | 1994-10-12 | Medinnova S F | Method |
-
1996
- 1996-02-28 IT IT96MI000378A patent/IT1282705B1/it active IP Right Grant
-
1997
- 1997-02-25 PT PT97906125T patent/PT906100E/pt unknown
- 1997-02-25 WO PCT/EP1997/000897 patent/WO1997031637A1/en active Search and Examination
- 1997-02-25 EP EP97906125A patent/EP0906100B1/en not_active Revoked
- 1997-02-25 DK DK97906125T patent/DK0906100T3/da active
- 1997-02-25 DE DE69727378T patent/DE69727378T2/de not_active Revoked
- 1997-02-25 JP JP53057997A patent/JP2001511763A/ja not_active Ceased
- 1997-02-25 ES ES97906125T patent/ES2213205T3/es not_active Expired - Lifetime
- 1997-02-25 AU AU20932/97A patent/AU2093297A/en not_active Abandoned
- 1997-02-25 AT AT97906125T patent/ATE258438T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK0906100T3 (da) | 2004-05-03 |
ITMI960378A1 (it) | 1997-08-28 |
DE69727378D1 (de) | 2004-03-04 |
IT1282705B1 (it) | 1998-03-31 |
ITMI960378A0 (ja) | 1996-02-28 |
PT906100E (pt) | 2004-06-30 |
AU2093297A (en) | 1997-09-16 |
WO1997031637A1 (en) | 1997-09-04 |
DE69727378T2 (de) | 2004-12-09 |
EP0906100A1 (en) | 1999-04-07 |
EP0906100B1 (en) | 2004-01-28 |
ATE258438T1 (de) | 2004-02-15 |
ES2213205T3 (es) | 2004-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8420667B2 (en) | Isoquinolinone derivatives as NK3 antagonists | |
US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
CN101588804B (zh) | 治疗或防治激素变异症状的方法 | |
EP1410800B1 (en) | Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts | |
EP1988076A1 (en) | Amide derivative or salt thereof | |
US5990114A (en) | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence | |
JP2001511763A (ja) | 尿失禁の治療のための5−ht▲下1a▼受容体アンタゴニストの使用 | |
WO2004014428A1 (ja) | 腸疾患および内臓痛の治療薬 | |
AU2019233449A1 (en) | Medicament for treating cough | |
JP2017014224A (ja) | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 | |
US20050165025A1 (en) | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | |
TW201808269A (zh) | 用於治療搔癢症及/或發癢之方法 | |
US20210401838A1 (en) | Identification of agents displaying functional activation of dopamine d2 and d4 receptors | |
JP2009520776A (ja) | 失禁治療方法 | |
Graul et al. | Desloratadine: Treatment of allergic rhinitis, Histamine H1 antagonist | |
JPH05507933A (ja) | Cnsおよび抗高血圧活性を有する置換1―(アルコキシフェニル)ピペラジン類 | |
US6864262B2 (en) | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof | |
AU670063B2 (en) | Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses | |
JPH07502517A (ja) | 精神病の治療のためのアリールインドールの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070328 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070521 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20071031 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071218 |